胶束化紫杉醇,注射用胶束化紫杉醇/L01CD01(Genexol PM Inj 30mg)

药店国别:

产地国家:韩国

处方药:

所属类别: 30毫克/5毫升/瓶 10瓶/盒

包装规格: 30毫克/5毫升/瓶 10瓶/盒

计价单位:

生产厂家中文参考译名:

生产厂家英文名:Samyang Biopharm

原产地英文商品名:Genexol-PM Inj(파클리탁셀)30mg/5mL/vial 10vial/Box

原产地英文药品名:Paclitaxel

中文参考商品译名:Genexol-PM注射用胶束(파클리탁셀)30毫克/5毫升/瓶 10瓶/盒

中文参考药品译名:胶束化紫杉醇

曾用名:L01CD01

简介

部份中文:Genexol-PM[抗肿瘤纳米药]处方资料(仅供参考)

商标名称:Genexol-PM,Paclitaxel/L01CD01

通用名称:注射用胶束化紫杉醇

韩文药名:중 파클리탁셀 30mg/5mL, 100mg/16.7mL

适应症:乳腺癌,肺癌,卵巢癌的一线治疗。

剂量

以每3周3小时的剂量静脉内施用300mg/m2的剂量; 根据以下剂量静脉内施用3小时,然后静脉内以60mg/m2的剂量施用顺铂; 其以每3周3小时的剂量以260mg/m 2的剂量静脉内施用。

包装:30mg/瓶,100mg/瓶。

生产商:韩国 Samyang BiopharmGenexol PM Inj

用药方案

紫杉醇Genexol PM是由Samyang开发的紫杉醇的专利新制剂。新制剂不含有毒的表面活性剂,并且允许向患者明显更高剂量的紫杉醇。

乳腺癌1)一线治疗转移性或复发性乳腺癌。2)标准化疗失败后转移性乳腺癌的二线治疗。

肺癌1)局部晚期或转移性非小细胞肺癌的一线治疗。

卵巢癌1)与其它化疗剂组合的一线治疗。

乳腺癌Genexol-PM以每3周3小时的初始剂量260mg/m 2静脉内施用。非小细胞肺癌根据以下剂量静脉内施用3小时Genexol-PM,然后静脉内以60mg/m 2的剂量施用顺铂。第一周期的Genexol-PM剂量:230mg/㎡第二周期的Genexol-PM的剂量卵巢癌Genexol-PM以每3周3小时的初始剂量260mg/m 2静脉内施用,其次是arboplatin AUC 5mg/mL·min。静脉内。

注射用胶束化紫杉醇(Genexol-PM,Paclitaxel/L01CD01)-是一种新型的抗肿瘤纳米药,为放射增敏剂的非小细胞肺癌、乳腺癌、卵巢癌治疗有效药

英文版说明

Genexol® PM Inj.Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy)Full descriptionGenexol-PM is a polymeric micelle formulated paclitaxel, free of Cremophor EL. Objectives with Genexol-PM are to reduce Cremophor EL-related toxicities and to increase therapeutic efficacy. Polymeric micelles are composed of hundreds of amphiphilic diblock copolymers.Block copolymers include poly-(ethylene glycol) used as nonimmunogenic carriers and biodegradable core-forming poly-(D,L-lactic acid) to solubilize hydrophobic drug. Genexol-PM showed 3-times higher maximum tolerated dose in mice vs.Taxol. Genexol-PM (vs. Taxol) showed 2-3-fold higher levels of paclitaxel in tissues including liver, spleen, kidney, lung, and tumors. In vivo antitumor efficacy of Genexol-PM was significantly higher than Taxol.Based on results from Phase I and II trials in Korea/US, the therapeutic dose recommended is 300mg/m2, much higher than Taxol (175 mg/m2). With favorable results from Phase II studies – Breast/Lung Cancer, Genexol-PM obtained a pre-market approval in Korea in July 2006A phase IIa pancreatic cancer trial is on-going in US.Patent informationSamyang has registered patents for the drug composition and method ofpreparation for Genexol-PM.The patents are registered in eight countries,including Korea, US, Japan, China, Canada, Mexico, Australia and Europe(EP). Europe includes Great Britain, Germany, Spain, France, Italy, Holland,Belgium, Switzerland and Sweden.- Genexol PM Inj.Genexol-PM was launched in the Korean market for breast cancer and non-small cell lung cancerGenexol-PM was launched in the Korean market for breast cancer and non-small cell lung cancer in February 2007.Market products that utilize paclitaxel, in particular Taxol? (“Taxol”), have encountered limited use due to the toxic side effects of Cremophor EL, which is a component used in the delivery system.Genexol-PM is specifically designed to avoid the use of Cremophor EL by successfully delivering paclitaxel and securing effective results.Genexol-PM is a sterile, lyophilized polymeric micellar formulation of paclitaxel that employs a colloidal carrier system to allow intravenous delivery of paclitaxel without Cremophor EL.Genexol-PM is now undergoing phase IIa clinical trials in the US for the treatment of advanced pancreatic cancer and phase I clinical trials in Korea for the treatment of ovarian cancer.Genexol-PM PaclitaxelThe new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients.Breast Cancer1) First-line treatment of metastatic or recurrent breast cancer.2) Second-line treatment of metastatic breast cancer after failure of standard chemotherapy.Lung Cancer1) First-line treatment of locally advanced or metastatic non-small cell lung cancer.Ovarian cancer1) First-line treatment in combination with other chemotherapeutic agents.Breast CancerGenexol-PM is administered at a dose of 300mg/㎡ intravenously over 3 hours every 3 weeks.Non-small cell lung cancerGenexol-PM is administered over 3 hours intravenously according to the dose below, followed by cisplatin at a dose of 60mg/㎡ intravenously.Dose of Genexol-PM for first cycle : 230mg/㎡Dose of Genexol-PM for second cycle and moreOvarian cancerGenexol-PM is administered at a dose of 260mg/㎡ intravenously over 3 hours every 3 weeks,followed by arboplatin AUC 5mg/mL·min. intravenously.Paclitaxel 30mg /vial , 100mg /vial30mg/5mL,100mg/16.7mLhttps://www.samyangbiopharm.com/eng/ProductIntroduce/injection01

 

我们希望人人都能吃的起药,看得起病! 我们希望让患者有权利选择自己经济能力范围内的药! 我们希望给国人提供一个能了解药品常识的平台,不再一无所知! 我们经过一年多时间反复深入的分析、研究,咨询了很多医学专家,药学专家,对比了近2000种重大疾病用药,总结了数百万字的药品知识。 我们建立医生China,是全国首个药品知识型公益社区。 www.yschn.com-医生China
药品价格查询,专业药品查询网站,药品说明书查询,药品比价 » 胶束化紫杉醇,注射用胶束化紫杉醇/L01CD01(Genexol PM Inj 30mg)

提供最优质的资源集合

立即查看 了解详情